Innovus Pharmaceuticals Announces Sensum+(R) to Directly Increase Sensitivity in Pre-Clinical Studies Supporting Its Mechanism of Action and the Human Use Experience

SAN DIEGO, CA--(Marketwired - Oct 21, 2015) - Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today that its product for reduced penile sensitivity, Sensum+®, significantly increased the sensitivity of the mice tails in the tail flick assay. The tail flick test is one test to measure heat-induced pain in animals. This reflexive response is an indicator of sensitivity in an organism and reduction or increase of sensitivity produced by test article. In this assay, Sensum+® significantly increased the sensitivity of mice tails by an average of ~25% starting at day 7 of the application consisting with the human use reports on the products. The Company expects to present its finding at upcoming urology meetings.

Dr. Bassam Damaj, President & Chief Executive Officer of Innovus Pharma, commented, "We are excited to have solid data on the mechanism of action of Sensum+® and we look forward to presenting it at upcoming urology conferences. "

Innovus Pharma has seven commercial partners for its Sensum+® product in over 60 countries including, Tabuk Pharma, Tramorgan, Elis Pharma, Orimed, Ovation Pharma, BoardMed and Oz Biogenics with over $55M in potential sales milestones and double digit royalty.

The partnered regions include Canada, United Kingdom, Middle East and North Africa, Vietnam, Myanmar and Turkey.

About Sensum+® and Reduced Penile Sensitivity(RPS)

Sensum+® is a patented blend of essential oils and natural botanicals including rose oil, sweet almond oil, cinnamon bark oil, and other extracts. The main ingredient of Sensum+® (cinnamon oil) works by activating the Transient Receptor Potential A1 (TRPA-1) channels responsible for the heat and cold sensation of the skin and results in an increase of sensation that current users welcome and appreciate. The safety and efficacy of Sensum+® was evaluated in 2 post marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for fourteen consecutive days followed by once daily for 8 weeks and as needed thereafter.

Reduced penile sensitivity is a major problem associated with many diseases such as hernia surgery, the use of anti-depressants, circumcision, multiple sclerosis and others. There are no approved products to treat RPS.

For more information visit www.sensumplus.com.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum⁺® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as EjectDelay^®, to successfully commercialize such products in Canada and in other countries and regions, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.